Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00518622 | Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED) | PHASE1 | COMPLETED | 40 | — | — | Jul 1, 2007 | Sep 1, 2008 | Aug 25, 2015 | - | — |
Number of participants who reported adverse experiences while on study medication as well as for 14 days after completion of study medication
Change from Baseline in Log10 IU/mL hepatitis C virus (HCV) ribonucleic acid (RNA) on Day 8
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 25 mg b.i.d. MK7009 |
| 2 | EXPERIMENTAL | 75 mg b.i.d. MK7009 |
| 3 | EXPERIMENTAL | 250 mg b.i.d. MK7009 |
| 4 | EXPERIMENTAL | 500 mg b.i.d. MK7009 |
| 5 | EXPERIMENTAL | 700 mg b.i.d. MK7009 |
| 6 | EXPERIMENTAL | 125 mg q.d. MK7009 |
| 7 | EXPERIMENTAL | 600 mg q.d. MK7009 |
| 8 | EXPERIMENTAL | Placebo |
| Name | Type | Description |
|---|---|---|
| Comparator: MK7009 | DRUG | Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8. |
| Comparator: Placebo | DRUG | MK7009 Placebo |
Inclusion Criteria: * Subject is a man or a woman aged 18 to 55 years of age. * Subject has chronic Hepatitis C * Subject is willing to not use alcohol for 2 weeks prior to therapy and through the study follow-up period Exclusion Criteria: * Patient has evidence of advanced liver disease. * Patie...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |